FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2289779858> ?p ?o ?g. }

• W2289779858 abstract "ABSTRACT Aim: The aims of Q2 were to assess whether the addition of BEV 7.5mg/kg q3/52 (12/12) to single agent CAP 1250mg/m2, 14 of every 21/7 (6/12), increases disease-free (DFS) and overall survival (OS) in CRC patients after resection of the primary; and to validate suggested, or discover new, biomarkers of BEV efficacy and toxicity. Methods: A phase III international randomised controlled trial, coordinated by the UK and recruiting in 6 countries. In addition to the collection of data on toxicity, DFS and OS, a biobank comprising 1350 FFPE blocks and 1000 germline DNA samples was established. Hypothesis-driven biomarkers (MSI status and epithelial/stromal ratio) and hypothesis-driven biomarkers (chomosomal instabiity, ras, raf, POLE and an 80-gene ion torrent panel) were analysed to assess their prognostic and predictive (BEV) utility. Results: 1941 patients were randomised in a 1:1 ratio and demographics and disease characteristics were well balanced between the two arms. DFS in the whole trial population demonstrates that BEV does not improve outcome in this setting (3 year DFS 75.2% for CAPBEV vs 78.2% for CAP: HR = 1.06; p = 0.54). Similarly OS was not improved (3 year OS 85.5% for CAPBEV vs 87.2% for CAP; p = 0.38; HR = 1.12). There may be a temporal trend in HRs (HRs: 1 year 0.83[0.61-1.13], 2 year 0.87[0.65-1.17], 3 year 1.32 [0.9-1.98]. Biomarker analyses confirm that high tumour stromal content confers a worse prognosis (3 year DFS HR 1.58 [1.22-2.05]; p = 0.001). MSS positivity was associated with a worse DFS in patients treated with CAP/BEV compared to those treated with CAP alone (n = 840; HR 1.43; p = 0.005) suggesting a negative predictive effect for BEV: For MSI positive patients, there was no significant difference in DFS between the two arms (n = 135; HR 0.74; p = 0.42). Conclusions: Q2 supports data from two other trials suggesting no role for BEV in the adjuvant setting of CRC. The Q2 biobank and linked database allows further collaborative biomarker hypotheses to be tested. There is a rationale for meta-analysis of all BEV adjuvant CRC studies to more fully explore the putative temporal effect of BEV administration on DFS. Disclosure: R.S. Midgley and D.J. Kerr: has received research funding in the form of an unrestricted educational grant from Roche. All other authors have declared no conflicts of interest." @default.
• W2289779858 created "2016-06-24" @default.
• W2289779858 creator A5024294734 @default.
• W2289779858 creator A5025282420 @default.
• W2289779858 creator A5038254746 @default.
• W2289779858 creator A5039504469 @default.
• W2289779858 creator A5040598662 @default.
• W2289779858 creator A5041416682 @default.
• W2289779858 creator A5048595984 @default.
• W2289779858 creator A5052024539 @default.
• W2289779858 creator A5054980046 @default.
• W2289779858 creator A5069612368 @default.
• W2289779858 creator A5072891727 @default.
• W2289779858 creator A5075475165 @default.
• W2289779858 creator A5080479952 @default.
• W2289779858 creator A5085287318 @default.
• W2289779858 date "2014-09-01" @default.
• W2289779858 modified "2023-09-26" @default.
• W2289779858 title "Final Results from Quasar2, a Multicentre, International Randomised Phase III Trial of Capecitabine (Cap) +/- Bevacizumab (Bev) in the Adjuvant Setting of Stage Ii/Iii Colorectal Cancer (Crc)" @default.
• W2289779858 doi "https://doi.org/10.1093/annonc/mdu438.10" @default.
• W2289779858 hasPublicationYear "2014" @default.
• W2289779858 type Work @default.
• W2289779858 sameAs 2289779858 @default.
• W2289779858 citedByCount "7" @default.
• W2289779858 countsByYear W22897798582015 @default.
• W2289779858 countsByYear W22897798582016 @default.
• W2289779858 countsByYear W22897798582017 @default.
• W2289779858 countsByYear W22897798582019 @default.
• W2289779858 countsByYear W22897798582021 @default.
• W2289779858 crossrefType "journal-article" @default.
• W2289779858 hasAuthorship W2289779858A5024294734 @default.
• W2289779858 hasAuthorship W2289779858A5025282420 @default.
• W2289779858 hasAuthorship W2289779858A5038254746 @default.
• W2289779858 hasAuthorship W2289779858A5039504469 @default.
• W2289779858 hasAuthorship W2289779858A5040598662 @default.
• W2289779858 hasAuthorship W2289779858A5041416682 @default.
• W2289779858 hasAuthorship W2289779858A5048595984 @default.
• W2289779858 hasAuthorship W2289779858A5052024539 @default.
• W2289779858 hasAuthorship W2289779858A5054980046 @default.
• W2289779858 hasAuthorship W2289779858A5069612368 @default.
• W2289779858 hasAuthorship W2289779858A5072891727 @default.
• W2289779858 hasAuthorship W2289779858A5075475165 @default.
• W2289779858 hasAuthorship W2289779858A5080479952 @default.
• W2289779858 hasAuthorship W2289779858A5085287318 @default.
• W2289779858 hasBestOaLocation W22897798581 @default.
• W2289779858 hasConcept C121608353 @default.
• W2289779858 hasConcept C126322002 @default.
• W2289779858 hasConcept C143998085 @default.
• W2289779858 hasConcept C2776694085 @default.
• W2289779858 hasConcept C2777802072 @default.
• W2289779858 hasConcept C2777909004 @default.
• W2289779858 hasConcept C2908647359 @default.
• W2289779858 hasConcept C526805850 @default.
• W2289779858 hasConcept C71924100 @default.
• W2289779858 hasConcept C99454951 @default.
• W2289779858 hasConceptScore W2289779858C121608353 @default.
• W2289779858 hasConceptScore W2289779858C126322002 @default.
• W2289779858 hasConceptScore W2289779858C143998085 @default.
• W2289779858 hasConceptScore W2289779858C2776694085 @default.
• W2289779858 hasConceptScore W2289779858C2777802072 @default.
• W2289779858 hasConceptScore W2289779858C2777909004 @default.
• W2289779858 hasConceptScore W2289779858C2908647359 @default.
• W2289779858 hasConceptScore W2289779858C526805850 @default.
• W2289779858 hasConceptScore W2289779858C71924100 @default.
• W2289779858 hasConceptScore W2289779858C99454951 @default.
• W2289779858 hasLocation W22897798581 @default.
• W2289779858 hasOpenAccess W2289779858 @default.
• W2289779858 hasPrimaryLocation W22897798581 @default.
• W2289779858 hasRelatedWork W1981679880 @default.
• W2289779858 hasRelatedWork W2098499757 @default.
• W2289779858 hasRelatedWork W2103551875 @default.
• W2289779858 hasRelatedWork W2131072420 @default.
• W2289779858 hasRelatedWork W2141665958 @default.
• W2289779858 hasRelatedWork W2168680994 @default.
• W2289779858 hasRelatedWork W2171232394 @default.
• W2289779858 isParatext "false" @default.
• W2289779858 isRetracted "false" @default.
• W2289779858 magId "2289779858" @default.
• W2289779858 workType "article" @default.